JP2020509761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509761A5 JP2020509761A5 JP2019549510A JP2019549510A JP2020509761A5 JP 2020509761 A5 JP2020509761 A5 JP 2020509761A5 JP 2019549510 A JP2019549510 A JP 2019549510A JP 2019549510 A JP2019549510 A JP 2019549510A JP 2020509761 A5 JP2020509761 A5 JP 2020509761A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- fusion protein
- acid mutation
- group
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710148158 | 2017-03-14 | ||
| CN201710148158.7 | 2017-03-14 | ||
| CN201810129427.X | 2018-02-08 | ||
| CN201810129427 | 2018-02-08 | ||
| PCT/CN2018/078925 WO2018166461A1 (en) | 2017-03-14 | 2018-03-14 | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509761A JP2020509761A (ja) | 2020-04-02 |
| JP2020509761A5 true JP2020509761A5 (https=) | 2020-11-19 |
| JP7181886B2 JP7181886B2 (ja) | 2022-12-01 |
Family
ID=63521973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549510A Active JP7181886B2 (ja) | 2017-03-14 | 2018-03-14 | 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12145974B2 (https=) |
| EP (2) | EP4470551A3 (https=) |
| JP (1) | JP7181886B2 (https=) |
| CN (1) | CN108570109B (https=) |
| ES (1) | ES3014984T3 (https=) |
| WO (1) | WO2018166461A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| AU2017358289C1 (en) | 2016-11-10 | 2025-05-08 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| CN110709520B (zh) | 2017-04-21 | 2024-04-05 | 株式会社柳韩洋行 | 用于产生双功能蛋白质及其衍生物的方法 |
| AU2019218147B2 (en) * | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| CN111273019A (zh) * | 2018-12-04 | 2020-06-12 | 山东博安生物技术有限公司 | 一种杜拉鲁肽elisa检测方法 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| CN111662373B (zh) * | 2019-03-05 | 2024-05-14 | 广东东阳光药业股份有限公司 | 一种多肽分子及其应用 |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| CN110357969B (zh) * | 2019-05-27 | 2022-03-08 | 北京志道生物科技有限公司 | 一种GLP1-EGFa异源二聚体蛋白、功能及方法 |
| CN114230663B (zh) * | 2019-05-30 | 2022-09-27 | 广东东阳光药业有限公司 | TrkA的抗体及其应用 |
| CN112279920B (zh) * | 2019-07-25 | 2024-01-16 | 安源医药科技（上海）有限公司 | FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途 |
| CN115322794B (zh) | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| CN111122880B (zh) * | 2020-02-14 | 2023-08-15 | 烟台大学 | 一种杜拉鲁肽的竞争elisa的检测方法及其试剂盒 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022002408A1 (en) * | 2020-07-02 | 2022-01-06 | Sanofi | Glp-1r agonist / fgf21 fusion proteins |
| BR112023003310A2 (pt) * | 2020-08-24 | 2023-05-02 | Univ Pennsylvania | Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas |
| US20230357411A1 (en) * | 2020-11-20 | 2023-11-09 | Sunshine Lake Pharma Co., Ltd. | Humanized anti-trka antibodies and uses thereof |
| EP4308610A4 (en) * | 2021-03-19 | 2025-07-16 | Sunshine Lake Pharma Co Ltd | USES OF FGF21 POLYPEPTIDES AND FUSION POLYPEPTIDES THEREOF |
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| CN117886927A (zh) * | 2022-10-14 | 2024-04-16 | 华南理工大学 | 一种提高血液半衰期的免疫球蛋白Fc变体及其应用 |
| CN115991793A (zh) * | 2023-01-16 | 2023-04-21 | 上海民为生物技术有限公司 | 具有多重活性的融合蛋白及其应用 |
| EP4545571A4 (en) * | 2023-01-18 | 2025-09-24 | Shanghai Minwei Biotechnology Co Ltd | TRIPLE ACTIVITY FUSION PROTEIN AND ITS USE |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| CN118955739B (zh) * | 2024-10-17 | 2025-02-18 | 华南理工大学 | 一种双靶点受体激动剂融合蛋白及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| GB0226787D0 (en) * | 2002-11-18 | 2002-12-24 | Qinetiq Ltd | Measurement of mitotic activity |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US20070253966A1 (en) * | 2003-06-12 | 2007-11-01 | Eli Lilly And Company | Fusion Proteins |
| CN1890371A (zh) | 2003-12-10 | 2007-01-03 | 伊莱利利公司 | 成纤维细胞生长因子的21突变蛋白 |
| WO2005072769A1 (en) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
| CA2557782A1 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| SI1751184T1 (sl) * | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
| EA011390B1 (ru) | 2004-09-02 | 2009-02-27 | Эли Лилли Энд Компани | Мутантные белки (мутеины) фактора роста фибробластов 21 |
| US8911726B2 (en) * | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| AU2008255352B2 (en) * | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| CA2693504A1 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| EP2206775B1 (en) * | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
| EP2296690B1 (en) | 2008-06-04 | 2016-11-30 | Amgen, Inc | Fgf21 mutants and uses thereof |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| EP2427207B1 (en) * | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| HRP20240135T1 (hr) | 2009-05-05 | 2024-04-12 | Amgen Inc. | Fgf21 mutanti i njihove upotrebe |
| US20120035099A1 (en) | 2009-06-11 | 2012-02-09 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| EP2440235A1 (en) | 2009-06-11 | 2012-04-18 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| CN101993496B (zh) * | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
| EP2496249B1 (en) * | 2009-11-03 | 2016-03-09 | Amylin Pharmaceuticals, LLC | Glp-1 receptor agonist for use in treating obstructive sleep apnea |
| EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| MX2014002260A (es) | 2011-08-31 | 2014-08-18 | Amgen Inc | Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1. |
| TW201315742A (zh) * | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| UY34346A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| CA2871656A1 (en) | 2012-06-11 | 2013-12-19 | Eli Lilly And Company | Fibroblast growth factor 21 variants |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| WO2014014796A1 (en) * | 2012-07-18 | 2014-01-23 | Eli Lilly And Company | Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains |
| TW201420606A (zh) * | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| WO2014037373A1 (en) * | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| SG11201608253XA (en) * | 2014-04-04 | 2016-10-28 | Kyowa Hakko Kirin Co Ltd | Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity |
| JO3568B1 (ar) * | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| SMT202100388T1 (it) * | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| US10844122B2 (en) * | 2015-05-06 | 2020-11-24 | Janssen Biotech, Inc. | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof |
| WO2017059371A1 (en) | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
-
2018
- 2018-03-14 EP EP24204936.9A patent/EP4470551A3/en active Pending
- 2018-03-14 EP EP18768644.9A patent/EP3596130B1/en active Active
- 2018-03-14 CN CN201810207528.4A patent/CN108570109B/zh active Active
- 2018-03-14 US US16/485,153 patent/US12145974B2/en active Active
- 2018-03-14 ES ES18768644T patent/ES3014984T3/es active Active
- 2018-03-14 WO PCT/CN2018/078925 patent/WO2018166461A1/en not_active Ceased
- 2018-03-14 JP JP2019549510A patent/JP7181886B2/ja active Active
-
2024
- 2024-08-15 US US18/805,686 patent/US20250084144A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509761A5 (https=) | ||
| CN108570109B (zh) | 包含免疫球蛋白Fc部分的双靶点融合蛋白 | |
| US8809499B2 (en) | Fusion protein of human fibroblast growth factor-21 and exendin-4 | |
| US20210079051A1 (en) | Growth differentiation factor 15 (gdf-15) constructs | |
| EP2468858B1 (en) | Fusion protein regulating plasma glucose and lipid, its preparation method and use | |
| US7576190B2 (en) | FGF-21 fusion proteins | |
| JP7781049B2 (ja) | デュアル機能タンパク質およびその誘導体を生産するための方法 | |
| JP2007505643A (ja) | 融合蛋白質 | |
| CA2575753A1 (en) | Muteins of fibroblast growth factor 21 | |
| AU2004303783A1 (en) | Muteins of fibroblast growth factor 21 | |
| US5854025A (en) | IGF-II analogues | |
| JPH05306297A (ja) | 新規なハイブリド形質転換成長因子 | |
| CN113735960B (zh) | 一种fgf重组蛋白治疗nash的应用 | |
| CN113747912A (zh) | 重组ccn结构域蛋白和融合蛋白 | |
| CA3060934C (en) | Method for producing dual function proteins and its derivatives | |
| WO2026082073A1 (zh) | 一种嵌合利钠肽或其变体及其应用 | |
| CN1119416C (zh) | 人白细胞介素2衍生物与人心钠素的融合基因、其蛋白产物及应用 | |
| US20210085754A1 (en) | Molecular design of recombinant protein drug | |
| CN114106194A (zh) | 一种用于治疗糖尿病和/或肥胖症的融合蛋白 | |
| HK40018939A (en) | Method for producing dual function proteins and its derivatives | |
| JPWO2023025120A5 (https=) | ||
| HK1229352A1 (zh) | 生长分化因子15(gdf-15)构建体 |